78 results about "Free drug" patented technology

The present invention provides a type of supramolecular hydrogel compound formed by self-assembly of effective ingredients of Macleaya cordata powder and flavonoid active molecules, a structure, a preparation method and an application. The supramolecular hydrogel compound has excellent selective antibacterial ability. While selectively killing pathogenic bacteria such as Staphylococcus aureus, it does not affect the activity of probiotics such as Bacillus subtilis and Enterococcus faecium in the intestine; it is particularly sensitive to methicillin-resistant Staphylococcus aureus (MRSA); it also has good anti-inflammatory effects and promotes wound healing. Among them, the natural supramolecular hydrogel formed by the self-assembly of effective ingredients of Macleaya cordata powder and flavonoid active molecules has a uniform morphology, good dispersion and stability, forms a gel without the need for excipients, and has the value of being developed into a carrier-free drug delivery preparation. The general structural formula of the compound is shown below:

The invention discloses a skin-targeted layered infiltration polypeptide modified liposome and a preparation method thereof, and relates to the technical field of skin delivery and infiltration. The preparation method comprises the following steps: S1, mixing phospholipid, cell-penetrating permeation-enhancing peptide, sterol and a fat-soluble active component to prepare a lipid organic solution containing polypeptide, and mixing a water-soluble active component with distilled water to prepare a water-phase solution; s2, assembling a liposome precursor solution by adopting the micro-nano fluidic chip, inputting the lipid organic solution from the lipid phase channel inlet, inputting the water phase solution from the water phase channel inlet, and assembling the lipid organic solution and the water phase solution in the micro-nano fluidic chip to obtain the liposome precursor solution; and S3, separating the free drug from the organic solution in the liposome precursor solution to obtain the polypeptide modified liposome with targeted skin layered infiltration.

The present application provides a detection method and use for neutralizing antibodies for therapeutic monoclonal antibodies, which is a CLB NAb assay developed through target-based drug depletion and drug-based NAb extraction for CMAB009 with high drug and target tolerance. Acid is typically used in the pretreatment of a sample to dissociate the drug / NAb complex. In order to improve the treatment effect, a two-step method involving an amphiphilic method and a bead method is adopted. Initially, EGFR-coated magnetic beads (target beads) are used to eliminate the majority of free drugs in a sample. Subsequently, after acid dissociation of the sample, NAb is captured with beads. NAb is neutralized and eluted by acid, and a biotinylated drug is added into an EGFR-coated flat plate for detecting NAb. A comprehensive experiment strategy is implemented, meanwhile, drug interference is relieved, and target tolerance is enhanced. Through troubleshooting and optimization, NAb determination is verified to be used for clinical sample analysis, so that the NAb is successfully applied to III-stage clinical immunogenicity NAb detection of CMAB009. The result shows that the integrated detection optimization strategy can greatly improve the key performance characteristics of CLB NAb detection, so that the potential immunogenicity and the influence of the potential immunogenicity on better biological development can be evaluated more reliably.

The invention belongs to the field of biological medicine, and particularly relates to an organic molecule self-assembly serving as a material-free medicine carrying system and a preparation method and application thereof. The invention provides a self-assembly body, the self-assembly body is composed of steroid series molecules, and a material-free drug loading system formed by self-assembly of the steroid series molecules is prepared by optimizing the molecular structure and critical aggregation concentration of the steroids. The material-free drug loading system can be used for loading drugs and preparing drug nano-composites. In the nano compound, the drug effect of the drug is improved, and the effects of reducing toxicity and improving efficiency can be achieved. Furthermore, if the used steroid molecules have biological activity, the pharmacological activity of the steroid molecules is not influenced after the steroid molecules are prepared into the drug nano-composite. The material-free drug loading system prepared by the invention has the advantages of no carrier and two nano preparations taking the traditional material as the carrier, and has a good prospect in the aspect of developing novel nano drug preparations.

The invention provides a mesenchymal stem cell composition as well as a preparation method and application thereof in knee joint products, and belongs to the technical field of medicines. The invention relates to application of a mesenchymal stem cell combined naringin derivative in preparation of medicines for treating osteoporosis and repairing knee joint injury and arthritis. The naringin derivative is prepared from naringin through an ether esterification reaction, the metabolic cycle of the naringin derivative is prolonged and the water solubility is improved while the original activity is maintained, so that the free drug concentration and tissue infiltration capacity in bones are improved, the bioavailability of the naringin derivative is improved, and the bioavailability of the naringin derivative is improved. The prepared mesenchymal stem cell composition can induce mesenchymal stem cell osteogenic differentiation and improve bone repair capacity, has a good intervention effect on osteoporosis, has a sustained and controlled release effect and prolongs medicinal time.

To provide a targeting moiety-drug conjugate that is biodegradable and biocompatible and exhibits high drug load as well as strong binding to a target antigen.SOLUTION: Provided is a conjugate comprising a targeting moiety and one or more linker-drug moieties covalently bonded to the targeting moiety, each linker-drug moiety including a multifunctional linker that connects the targeting moiety to one or more drug units through intermediacy of a releasable assembly unit for each drug unit and connects a hydrophilic group to the drug units of each linker-drug moiety, the releasable assembly units being capable of releasing a free drug in proximity to a target site targeted by the targeting moiety, the multifunctional linker comprising a peptide moiety between the targeting moiety and the hydrophilic group, and the peptide moiety includes at least two amino acids.SELECTED DRAWING: Figure 1

The application discloses a high-affinity rabbit monoclonal antibody against dupilumab and an application thereof, and relates to the technical field of monoclonal antibody preparation.The high-affinity rabbit monoclonal antibody provided by the application is a first antibody or a second antibody;the amino acid sequence of the heavy chain of the first antibody is shown in SEQ ID NO.8, and the amino acid sequence of the light chain is shown in SEQ ID NO.9;the amino acid sequence of the heavy chain of the second antibody is shown in SEQ ID NO.17, and the amino acid sequence of the light chain is shown in SEQ ID NO.18.The application also provides nucleic acid molecules for encoding the rabbit monoclonal antibody, a recombinant strain and other biological materials, and a drug and a product for detecting dupilumab.The rabbit monoclonal antibody provided by the application has high affinity, detection sensitivity and specificity for dupilumab, and can be used for diagnosing the total drug concentration and free drug concentration of dupilumab (DUPILUMAB) in the body of an injected patient; and has no cross reaction with human IgG4 and human total IgG. Dupilumab ) in the body of an injected patient; and has no cross reaction with human IgG4 and human total IgG.

The present invention discloses a double-layer sealed zero-pressure needle-free drug-adding connector, including an outer shell, an elastic seal, a one-way seal and a screw base, wherein the bottom end of the outer shell is provided with an annular connector snap-in groove; the upper end of the screw base is inserted into the connector snap-in groove; the elastic seal is arranged in the outer shell, and the interior of the elastic seal is hollow; the bottom end face of the elastic seal is provided with an annular snap-in groove and a downwardly protruding convex column; the one-way seal is in a conical shape, and the one-way seal is arranged in the screw base; the inner cavity of the one-way seal is a conical cavity, and a slit is provided at the bottom end of the one-way seal; the bottom end face of the elastic seal is pressed against the top end face of the one-way seal, and the convex column is tightly inserted into the inner cavity of the one-way seal. The double-layer sealed zero-pressure needle-free drug-adding connector of the present invention can avoid the generation of pressure at the end of infusion and improve the comfort of infusion for patients.

The invention provides a full-automatic detection device and method for the concentration of free drugs in blood. The full-automatic detection method adopts a full-automatic detection device and comprises the following steps: (1) loading a blood sample to a protein purification chromatographic column by adopting a pump 1 and an automatic sampler, removing protein components in the blood sample, and retaining free drug components on the protein purification chromatographic column; (2) enabling free drug components in the protein purification chromatographic column to flow into a trapping column and enriching the free drug components in the trapping column; and (3) enabling the free drug components in the trapping column to flow into an analytical column, separating, and detecting in a triple quadrupole mass spectrometer. Through the specific full-automatic detection device, the problems that total drug concentration monitoring cannot meet clinical treatment requirements, and the free drug pretreatment process is complex, long in time and high in cost are solved, clinical individualized drug administration can be assisted, the drug curative effect is improved, and the toxic and side effects of drugs are reduced.

There is disclosed a system for delivery of a drug in vivo. In the delivery system, the extent of the delivery of the drug is monitorable and / or controllable by using chemical exchange saturation transfer magnetic resonance imaging (CEST MRI). The delivery system has elements of a solvent system of dimethyl sulfoxide (DMSO) or its analogs for carrying the drug, detecting the delivery and / or biodistribution the drug, and / or interaction of the drug compartmentalized in vivo by way of directly imaging the solvent system by the CEST MRI due to the inherent contrast of the solvent system.

The invention discloses a medicine balloon dilatation catheter which comprises a balloon and a support arranged outside the balloon, the support is in a net pipe shape and can dilate and contract along with the balloon, the dilatation diameter of the support is smaller than the dilatation diameter of the balloon during dilatation, and the dilatation catheter further comprises a medicine coating coated on the outer portion of the balloon. The drug coating comprises a plurality of magnetic drug particles; in a contraction state, the medicine particles are positioned between the balloon and the stent; in the expansion state, part of the sacculus swells out of the stent from the meshes of the stent to form a plurality of protruding parts, and the medicine particles are located on the protruding parts respectively. According to the drug balloon dilatation catheter, under the action of an in-vitro magnetic field, free drug particles generated in the dilatation process of the dilatation catheter can migrate to a vascular intima, meanwhile, the magnetic field can also prevent the drug particles squeezed into a blood vessel from being washed by blood to be separated from the blood vessel, and drug loss in the dilatation process can be reduced. And the stent is arranged outside the balloon, so that the medicine loss of the dilating catheter in the conveying process can be reduced.

The invention relates to tedizolid gel and a preparation method thereof. The tedizolid gel is prepared from the following raw materials and auxiliary materials: an active component, a gel matrix, an alcohol solvent, a bacteriostatic agent, a pH regulator and water, the active component is tedizolid or ester thereof, or pharmaceutically acceptable salt thereof; the gel matrix is carbomer. The tedizolid gel can increase the local tissue free drug concentration of the skin of the bacterial infection part of an organism through transdermal absorption, so that the bacteriostatic activity of the tedizolid gel is better played, the treatment effect on local acute bacterial skin and skin soft tissue infection is improved, and the adverse reaction is reduced.

The application discloses a polymer vesicle-stabilized drug-iodized oil emulsion and a preparation method and application thereof, to realize safe and efficient transarterial chemoembolization (TACE) treatment of hepatocellular carcinoma in situ. The drug-iodized oil emulsion system has the following advantages: simple preparation, convenient size adjustment, excellent stability, near-zero order and sustained controllable drug release rate, low blood drug concentration after transarterial embolization, and the retention time and retention amount of the drug in the liver are superior to those of free drug-iodized oil emulsion used in clinical treatment, the tumor can be completely eradicated, angiogenesis can be effectively inhibited, and adverse reactions can be reduced. In general, the polymer vesicle-stabilized drug-iodized oil emulsion has the advantages of high stability and sustained controllable drug release, and can greatly improve the embolization chemotherapy effect of hepatocellular carcinoma, and provide a safe and efficient TACE strategy.

The present invention provides a neutrophil-based bone marrow-targeted drug delivery carrier and its application. The bone marrow is the apoptosis site of neutrophils, and a large number of neutrophils enter the bone marrow and undergo apoptosis every day. Free drugs or drug-loaded nanocarriers are combined with neutrophils by endocytosis by neutrophils or physical / chemical grafting on the surface. Neutrophils cultured in vitro can be used as drug carriers to achieve bone marrow-targeted delivery of drugs in vivo. The drugs can effectively penetrate vascular endothelial cells through neutrophils and enter the bone marrow, effectively increasing the drug concentration at the bone marrow site, thereby improving the therapeutic effect of bone-related diseases and achieving drug-targeted delivery at the bone marrow site.

The invention belongs to the technical field of biological medicine and nano-drugs, and discloses a liposome nano-particle for treating cardiomyopathy and a preparation method and application thereof, the liposome nano-particle is composed of phospholipid, cholesterol, functionalized lipid and a drug for treating cardiomyopathy according to a specific mass ratio, wherein the mass ratio of the phospholipid to the cholesterol to the functionalized lipid is (60-80): (10-20): (5-20), and the mass ratio of the medicine to the total lipid is (1: 10)-(1: 50). The preparation method comprises the steps of lipid film formation, vacuum drying, buffer solution hydration, extrusion granulation, purification sterilization and the like, and targeting molecules can be further connected. By optimizing a lipid prescription and a process, nanoparticles with uniform particle size, high encapsulation efficiency and good stability are successfully prepared, myocardial targeted delivery and slow release of drugs can be realized, enrichment of the drugs in myocardial tissues can be remarkably improved by the preparation, the preparation shows a treatment effect superior to that of non-targeted preparations and free drugs in a cardiomyopathy model, and the preparation has a wide application prospect. And a new strategy is provided for accurate and efficient treatment of cardiomyopathy.

The invention relates to the technical field of drug delivery systems, and provides electrostatic spinning microspheres of ellagic acid and urolithin and a preparation method of the electrostatic spinning microspheres. According to the preparation method disclosed by the invention, the nano-microspheres prepared from alginate and chitosan are successfully prepared by utilizing an electrostatic spinning technology, and ellagic acid and metabolin thereof, namely urolithin, are effectively encapsulated, so that a guarantee is provided for efficient delivery of medicines. The prepared electrostatic spinning microspheres are uniform in particle size distribution, the packaging efficiency reaches 60-88%, and FTIR and TGA prove that the medicine is successfully embedded and has good thermal stability. Compared with free drugs, the drug-loaded microspheres still show excellent antioxidant activity, and the DPPH and ABTS removal activity before and after EA and Uro C are encapsulated is the highest. An in-vitro digestion experiment shows that compared with a free drug, the drug loss of the microsphere in stomach and intestine stages is reduced by 32%-69%, the drug can be protected to smoothly reach the colon to play a role, and the bioavailability of the drug is greatly improved.

This invention discloses the application of plant extracts in the preparation of drugs that inhibit canine parvovirus, belonging to the field of biomedical technology. The plant extract is at least one selected from phlorizin, neomethylhesperidin-dihydrochalcone, tribulus terrestris saponin, stevia glycoside, soy isoflavones, berberine hydrochloride, diosgenin, and silymarin. Through in-depth research on various plant extracts, this invention has found that phlorizin, neomethylhesperidin-dihydrochalcone, tribulus terrestris saponin, stevia glycoside, soy isoflavones, berberine hydrochloride, diosgenin, and silymarin all exhibit significant inhibitory effects on canine parvovirus, with soy isoflavones showing particularly outstanding effects. This research provides a novel natural drug option for the prevention and treatment of canine parvovirus. This invention not only expands the application scope of natural plant extracts in the veterinary medicine field but also provides important technical support for the development of novel, highly effective, safe, and side-effect-free drug formulations for the prevention and treatment of canine parvovirus.

The invention relates to the technical field of biological medicine, in particular to a preparation method and application of a drug delivery carrier based on dunaliella salina cells, and the method comprises the following steps: selecting dunaliella salina for standardized culture to obtain dunaliella salina living cells; the target drug and the dunaliella salina living cells are loaded into the dunaliella salina living cells through an endocytosis method; free drug molecules are removed through centrifugation, and the dunaliella salina cell drug delivery carrier is obtained. Efficient drug loading is achieved by activating an endocytosis pathway, the highest quercetin loading rate reaches 92%, and the quercetin loading rate is remarkably superior to that of a co-incubation method and an electroporation method; the dunaliella salina cell carrier is excellent in biocompatibility, and the cell survival rate is gt; no organ toxicity exists in a mouse experiment; the medicine can be slowly released in intestinal tracts, the retention time is prolonged, the anti-tumor effect in a colorectal cancer model is remarkable, and the immunoregulation effect can be enhanced; the preparation process is simple and controllable, special equipment is not needed, and a new scheme is provided for constructing an efficient delivery system for natural drugs.

The invention relates to the technical field of biological medicine, in particular to centipeda minima extracellular vesicle nose drops and a preparation method and application thereof.The centipeda minima extracellular vesicle nose drops comprise active ingredients, plant extracellular vesicles (Cm-EVs) derived from centipeda minima, the concentration of the plant extracellular vesicles (Cm-EVs) is 1 * 10 < 10 >-5 * 10 < 11 > particles / ml; the key active substances are as follows: the content of the Cm-EVs naturally encapsulated sesquiterpene lactone compound centipederin is more than or equal to 50 micrograms per milliliter (detected by HPLC-MS); the pharmaceutical auxiliary materials comprise 0.05 to 0.2 percent (w / v) of sodium hyaluronate, 0.8 to 1.0 percent (w / v) of NaCl and 0.005 to 0.02 percent (v / v) of polysorbate 80; the method has the beneficial effects that the targeted enrichment capability is realized: mucous membrane adhesion is enhanced through surface pectin protein, and the nasal cavity residence time is prolonged to 6 hours (the free medicine is less than 1 hour); the nano-scale particle size (80-200nm) can efficiently penetrate through the mucous layer, and the nasal mucosa drug concentration reaches 20 times of the plasma concentration (rat pharmacokinetic data); the long-acting slow-release property is as follows: the active ingredients are protected by the lipid bilayer, the cumulative release rate of the centipederin within 72 hours reaches 82%, and the free medicine can be completely released within 24 hours.

The invention relates to conjugates of biologically active compounds, wherein such a conjugate is comprised of a sequence of amino acids containing a tripeptide that confers selective cleavage by tumor tissue homogenate for release of free drug and / or improves biodistribution into the tumor tissue in comparison to normal tissue homogenate from the same species, wherein the normal tissue is the site of an adverse event associated with administration to a human subject in need thereof of a therapeutically effective amount of a comparator conjugate whose amino acid sequence is a dipeptide known to be selectively cleavable by Cathepsin B.

The invention discloses dexamethasone eye emulsion supramolecular hydrogel and a preparation method thereof, and belongs to the technical field of medicines. The dexamethasone eye emulsion supramolecular hydrogel is prepared from the following components in percentage by mass volume: 0.02 to 0.06 percent of dexamethasone, 0.5 to 5 percent of liquid oil, 1 to 6 percent of emulsifier and 1 to 5 percent of polyphenol. According to the dexamethasone ophthalmic emulsion supramolecular hydrogel provided by the invention, dexamethasone is used as a main drug, and a nanoemulsion is used as an insoluble drug carrier to improve the solubility of the dexamethasone ophthalmic emulsion supramolecular hydrogel; the emulsifier on the surface of the nanoemulsion can be self-assembled with polyphenol through hydrogen-bond interaction to form a supramolecular hydrogel network. After the preparation is dropped into the conjunctival sac, the drug-loaded nano-emulsion is gradually released and the free drug is further released under the shear thinning action caused by tear dilution and blinking, so that the long-acting treatment concentration is maintained on the ocular surface, and the defects that the drug is easily lost due to nasolacrimal duct drainage, the retention time of the ocular surface is short and the like in the traditional eye drops are effectively overcome.

The invention relates to the technical field of biological medicine, in particular to pogostemon cablin alcohol lipid cubic liquid crystal nanoparticles as well as a preparation method and application thereof. The pogostemon cablin alcohol lipid cubic liquid crystal nanoparticles comprise the following components: glyceryl monooleate, polyethylene glycol 400, poloxamer 407, D (+)-glucose and pogostemon cablin alcohol. The pogostemon cablin alcohol lipid cubic liquid crystal nanoparticle is of a core-shell structure, a shell is of a skeleton structure jointly formed by the glyceryl monooleate, the polyethylene glycol 400, the poloxamer 407 and the D (+)-glucose, and a core is the pogostemon cablin alcohol. The patchouli alcohol lipid cubic liquid crystal nanoparticles are good in in-vitro stability, have a slow release effect compared with free drugs, and have good development and application prospects in the field of chemotherapeutic intestinal injury treatment.

This invention discloses the use of an anti-PEG single-chain antibody, PEG-scFv, in conjunction with indicator liposomes for the separation and quantitative analysis of loaded and free drugs contained in small-volume biological samples containing trace amounts of PEGylated nanodrugs. The invention also discloses a method for separating and quantitatively analyzing trace amounts of loaded and free drugs in small-volume samples using PEG-scFv and indicator liposomes, comprising: adding PEG-scFv and indicator liposomes to the sample, incubation, centrifugation, aspirating the supernatant, and detecting the content of free drug in the supernatant. This separation method achieves both efficient separation of trace amounts of PEGylated nanodrugs in small-volume samples and accurate quantification of loaded and free drugs. Furthermore, the method uses the sedimentation efficiency of the indicator liposomes to indicate the separation efficiency of the PEGylated nanodrugs, meeting the consistency detection requirements for samples with unknown concentrations.

Disclosed in the present application are a precursor compound based on edaravone structure, or a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. The compound or the pharmaceutically acceptable salt thereof of the present application has relatively good water solubility, and can release the free drug edaravone in the brain to cause the concentration of the free drug edaravone accumulated in the brain being significantly higher than that of bulk drug edaravone, thereby prolonging the residence time of the drug in the brain, and thus improving the action effect of the drug.

The invention discloses a method for verifying combination of a small molecule drug and a cell target protein, and belongs to the field of cytobiology and molecular biology. The method comprises the following steps: combining a small molecule drug with a cell target protein, and reducing the content of a free drug; the primary antibody is combined with cell protein to form a primary antibody complex; capturing a primary antibody complex by the PVDF membrane for incubating the secondary antibody; taking out the PVDF membrane, cleaning, and splitting miscellaneous protein in the solution to dissociate residual drugs; and detecting the amount of residual free drugs by HPLC, and analyzing data. The method solves the problem that small molecule-protein binding is difficult to directly detect in a traditional method, and the sensitivity is improved through combination of immunocapture and liquid chromatography or mass spectrometry quantitative detection. According to the method, a trace reagent system is adopted, the dosage of a single sample antibody is reduced by 70%, the PVDF membrane can be repeatedly used for 3-5 times, and the comprehensive detection cost is reduced by 60-80%. Various drug properties can be adapted (by adjusting lysis conditions such as pH / temperature).

This application relates generally to the field of implants and more specifically to drug eluting vascular stents and methods of making and using same. Specifically, this technology relates to controlled release of drug from an implant and particular from a stent without the presence of polymer or alteration of the implant surface.

The invention relates to the technical field of pharmaceutical co-crystals, and particularly discloses a cariprazine and quercetin pharmaceutical co-crystal and a preparation method and application thereof.The cariprazine and quercetin pharmaceutical co-crystal is prepared by mixing cariprazine and quercetin according to the proportion, adding a good solvent n-propyl alcohol till complete dissolution, dropwise adding a poor solvent into the mixed solvent till the mixed solvent is in a supersaturated state to obtain a mixed solution, and then adding the mixed solution into a reaction kettle to obtain the cariprazine and quercetin pharmaceutical co-crystal. And volatilizing the solvent in the mixed solution by adopting a solvent evaporation crystallization method, so that the cariprazine and the quercetin form intermolecular hydrogen-bond interaction, and the cariprazine and quercetin pharmaceutical co-crystal is obtained. A powder dissolution experiment result of the cariprazine and quercetin eutectic crystal shows that the dissolution rate of the cariprazine is reduced compared with the release rate of a free drug under a neutral condition, and a potential slow release effect is shown, so that the cariprazine and quercetin pharmaceutical eutectic crystal can be prepared into a muscle injection, and the clinical application prospect is broad. The traditional Chinese medicine composition has the potential of treating schizophrenia for a long time and reducing muscle stimulation.

The present application belongs to the technical field of biological medicine, and particularly relates to a method for predicting the in-vitro immunogenicity of biological drugs based on co-culture of dendritic cells and T cells. The present application constructs an in-vitro immunogenicity evaluation method with immature dendritic cells as the core. By limiting the dendritic cell differentiation time, not introducing any maturation stimulating factors, and removing free drug molecules after antigen treatment and then co-culturing with T cells, the T cell activation is mainly derived from the antigen presentation process itself, thereby effectively reducing the interference of drug pharmacological action or non-specific immune activation on the detection results. At the same time, the present application discards the traditional detection method relying on T cell proliferation or cytokine release, and adopts the early activation state of T cells as the evaluation index, thereby reducing the experimental complexity, shortening the experimental period, and solving the technical problem that the specificity is insufficient and the experimental period is too long to be considered in the existing in-vitro immunogenicity evaluation method.

The invention provides a veterinary enrofloxacin lipid nanoemulsion and a preparation method and application thereof, and the veterinary enrofloxacin lipid nanoemulsion comprises the following components by mass: 5% of enrofloxacin, 5-10% of EL40, 5-10% of soybean lecithin, 0.1-0.3% of CMC-Na, 0.1-0.5% of saccharin sodium, 0.1-0.5% of Arabic gum, and the balance of sterile water. The particle size is 140-150 nm, the PDI is less than or equal to 0.35, and the Zeta potential is-30 to-50 mV; the encapsulation efficiency is greater than or equal to 99.5%, and the drug loading capacity is greater than or equal to The encapsulation efficiency and the drug loading capacity are high, the drug effect maximization is ensured, the encapsulation efficiency is larger than or equal to 99.5%, the drug loading capacity is larger than or equal to 4.8%, the drug is almost completely wrapped by the lipid carrier, the free drug loss is reduced, and the bioavailability is remarkably improved; the high encapsulation efficiency can reduce the degradation of the drug in the gastrointestinal tract and improve the concentration of the target tissue drug.

This invention discloses a method for determining the encapsulation efficiency of amphotericin B liposomes for injection, comprising the following steps: separating the amphotericin B liposome solution for injection using solid-phase extraction adsorption to obtain an encapsulated drug solution and a free drug solution; and determining the drug mass concentration C in the encapsulated drug solution using HPLC. 包封 Drug mass concentration C in free drug solution 游离 And the total drug concentration C in the amphotericin B liposome solution before separation 总 The encapsulation efficiency and recovery rate of amphotericin B liposomes were calculated. This invention utilizes a macroporous copolymer of divinylbenzene and N-vinylpyrrolidone as the adsorbent in a solid-phase extraction adsorption method. Its macroporous structure provides ample adsorption sites while avoiding physical compression and damage to the liposome vesicles. This method achieves the separation of free amphotericin B liposomes from the encapsulated drug, exhibiting good reproducibility, high accuracy, simple operation, and high recovery rate.